Memulai Kembali Terapi Antikoagulan setelah Perdarahan Gastrointestinal

Oleh :

Alexandra Francesca Chandra

Memulai kembali terapi antikoagulan setelah timbulnya komplikasi perdarahan gastrointestinal, terutama yang berat atau mengancam nyawa, bukanlah hal yang mudah bagi klinisi. Perdarahan adalah komplikasi utama dan tersering dari terapi antikoagulan.[1]

Setiap tahunnya, kejadian perdarahan akibat antikoagulan bervariasi antara 2–5% untuk perdarahan mayor, 0,5–1% untuk perdarahan fatal, dan 0,2–0,4% untuk perdarahan intrakranial. Perdarahan akibat antikoagulan paling sering terjadi di sistem gastrointestinal, yaitu sebanyak 40%.[1–3]

Sixflashphoto_Wikimedia-commons_2019

Di satu sisi terapi antikoagulan jangka panjang penting untuk mencegah kejadian tromboemboli, seperti stroke, tetapi terjadinya perdarahan membuat banyak klinisi ragu untuk melanjutkan terapi antikoagulan. Hal ini menimbulkan dilema klinis, seolah-olah klinisi harus “memilih” antara menghentikan terapi antikoagulan dengan konsekuensi risiko tromboemboli, atau melanjutkan terapi antikoagulan dengan konsekuensi perdarahan berulang kembali.

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Rubboli, A., C. Becattini, and F.W. Verheugt, Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol, 2011. 3(11): p. 351-8. https://www.ncbi.nlm.nih.gov/pubmed/22125670
2. Little, D., et al., Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. Thrombosis research, 2019. 175: p. 102-109. https://www.thrombosisresearch.com/article/S0049-3848(19)30029-5/fulltext
3. Witt, D.M., What to do after the bleed: resuming anticoagulation after major bleeding. Hematology. American Society of Hematology. Education Program, 2016. 2016(1): p. 620-624. https://www.ncbi.nlm.nih.gov/pubmed/27913537
4. Qureshi, W., et al., Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol, 2014. 113(4): p. 662-8. https://www.ncbi.nlm.nih.gov/pubmed/24355310
5. Witt, D.M., et al., Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med, 2012. 172(19): p. 1484-91. https://www.ncbi.nlm.nih.gov/pubmed/22987143
6. Staerk, L., et al., Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, 2015. 351: p. h5876. https://www.bmj.com/content/bmj/351/bmj.h5876.full.pdf
7. Sengupta, N., et al., The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol, 2015. 110(2): p. 328-35. https://www.ncbi.nlm.nih.gov/pubmed/25512338
8. Little DHW, Sutradhar R, Cerasuolo JO, et al. Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. CMAJ. 2021;193(9):E304
9. Heuschmann, P.U., et al., Three-month stroke outcome: the European Registers of Stroke (EROS) investigators. Neurology, 2011. 76(2): p. 159-65. https://www.ncbi.nlm.nih.gov/pubmed/21148118
10. Koton, S., et al., Stroke incidence and mortality trends in US communities, 1987 to 2011. Jama, 2014. 312(3): p. 259-68. https://www.ncbi.nlm.nih.gov/pubmed/25027141
11. Sengupta, N., et al., Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. Clin Gastroenterol Hepatol, 2018. 16(12): p. 1893-1900.e2. https://www.ncbi.nlm.nih.gov/pubmed/29775794
12. Majeed, A., et al., Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost, 2017. 117(3): p. 491-499. https://www.ncbi.nlm.nih.gov/pubmed/28004062